Michigan Medicine

Annual Hematologic
Malignancies Symposium




Saturday, October 19, 2024

7:30 am – 4:30 pm
Check in and continental breakfast at 7:00 am

THE KENSINGTON HOTEL

3500 SOUTH STATE STREET , ANN ARBOR, MICHIGAN 48108 

There is no cost to attend

The Speakers

Keynote Speaker

P. Leif Bergsagel, MD
David F. and Margaret T. Grohne Professor of  Novel Therapeutics for Cancer Research
Director,  Mayo Clinic SPORE in Multiple Myeloma
Co-Director, Hematologic Malignancies Program  Mayo Clinic Cancer Center
Division of Hematology, Mayo Clinic, Phoenix, AZ


Michigan Medicine

Division of Hematology Oncology

Michigan Medicine
Division of Hematology Oncology

Michigan Medicine
Division of Hematology Oncology

Michigan Medicine
Molecular and Genomic Pathology

Michigan Medicine

Division of Hematology Oncology:  Adult Blood and Marrow Transplantation

Michigan Medicine
Division of Hematology Oncology

Michigan Medicine

Pharmacy

Michigan Medicine

Pharmacy

City of Hope Comprehensive Cancer Center, Los Angeles, CA

Michigan Medicine
Division of Hematology Oncology

Michigan Medicine
Division of Hematology Oncology

Michigan Medicine

Division of Hematology Oncology;
Section Head, Lymphoma and Myeloma

Target Audience
This symposium is intended for physicians, physicians in training (residents/fellows), medical students, pharmacists, and advanced practice providers in the field of malignant hematology.

Description with expected results
The University of Michigan Rogel Cancer Center (UMRCC) is an NCI-designated comprehensive cancer center with a history of excellence in cancer care, education, and research.  The UMRCC catchment area includes the entire State of Michigan, its ≈10M residents, and ≈750 community medical oncologists.  After completing this activity participants will be able to utilize current, state of the art updates in the diagnosis, risk stratification, and treatment of all hematologic malignancies.  They will also be able to enroll patients to the ground breaking and often lifesaving clinical trials. After completion of this activity, patient outcomes will be improved by having been enrolled in the appropriate clinical trials designed specifically to treat Hematologic Malignancies.

Faculty Planner
Ryan Wilcox, MD, PhD
Department of Internal Medicine,
Division of Hematology/Oncology
Section Head, Lymphoma & Myeloma


Financial Disclosure Information

Individuals in control of content have no relevant financial relationships with companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 


Accreditation and Credit Designation

The University of Michigan Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Michigan Medical School designates this live activity for a maximum of - AMA PRA Category 7.25 Credit(s)TM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Please note: Attendance must be registered within 6 months to be awarded credit.  To complete an evaluation for this session please login to MiCME and go to the Claim Credits and View Certificates on the Credit Center card.  Locate the activity under Awarded Credits and complete the evaluationThere will also be a QR code will be available on site at the symposium.

 For additional information contact Jennifer Fossum  jpfossum@umich.edu